Stay updated on Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial page.

Latest updates to the Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe NIH announcement about its website transition and the use of “Super Intelligence” terminology is no longer displayed. The study page continues to show a 403 Forbidden error.SummaryDifference1%

- Check17 days agoChange DetectedThe record for a study of nivolumab and relatlimab in advanced microsatellite-stable colorectal cancer has been replaced by a 403 Forbidden error page, so the study details are unavailable.SummaryDifference20%

- Check24 days agoChange DetectedA site-wide notice announces a transition in NIH content from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check30 days agoChange DetectedThe ClinicalTrials.gov footer revision label changes from v3.7.1 to v3.7.2; the page remains a 403 Forbidden error page.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now shows a 403 Forbidden error, indicating the study record is inaccessible. This change replaces the expected study content with the standard error view and related header/footer.SummaryDifference20%

Stay in the know with updates to Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial page.